BPC-157
Research Reliability -
A gastric-derived peptide widely discussed for tissue and gut repair — a regulated research/clinical compound, not an OTC supplement.
Appetite
Mood
Sleep
BPC-157
Description
BPC-157 ("Body Protection Compound") is a synthetic peptide fragment studied in preclinical models for promoting angiogenesis and accelerating healing in tendon, ligament, and gut tissue, which has made it one of the most talked-about compounds in injury-recovery biohacking circles. Its regulatory status has been genuinely turbulent: the FDA placed it on a restricted compounding list in 2023 over safety concerns, removed it from that list in April 2026, and it remains under active FDA Pharmacy Compounding Advisory Committee review as of mid-2026 — meaning it is not an FDA-approved drug, not a legal over-the-counter supplement, and is officially designated Research Use Only outside of a prescribing/compounding pharmacy relationship. Human controlled-trial data remains limited relative to its popularity.
Effects
First days–weeks
used for tissue and gut repair in research settings
Weeks
reported recovery benefits accumulate
Note
not a felt daily supplement; requires clinical oversight
How it Feels
This is a peptide used in research and clinical contexts, not an over-the-counter supplement, and it should only be considered under a qualified provider. Users pursuing injury or gut recovery report gradual improvement over weeks rather than any acute sensation. Sourcing and legality vary, which is a real consideration.
Usage
Entry Dose
Research/clinical use only — not a self-administered OTC supplement
Standard Dose
Research protocols use 250–500mcg, by prescription/compounding only
Max Dose
Set by prescribing physician
Onset
Days–weeks (tissue repair)
Combinations
Pairs well with
Synergistic
Collagen — provides the structural raw material that BPC-157's proposed tissue-repair mechanisms would act on
Physician-supervised rehab protocols — peptide therapy is generally framed as an adjunct, not a replacement, to physical therapy
Avoid combining
Contraindicated
Self-sourcing or self-administering outside a physician/compounding-pharmacy relationship — legal and quality-control risk
Active or history of cancer — angiogenic mechanisms are a theoretical concern in oncology
Competitive athletics — check current anti-doping status before use
Pregnancy — contraindicated
Biomarkers to Track
Subjective
(Daily)
Pain levels at injury site (1–10)
Range of motion
Recovery timeline versus expected healing
Objective
(Quarterly)
Physician-ordered imaging (MRI/ultrasound) at injury site
Inflammatory markers (hs-CRP)
Functional movement screen
A research peptide, not an approved supplement. Human safety and efficacy data are limited, and sourcing and legality are real concerns.
Anyone without qualified medical oversight, and pregnant women.
Self-directing it from unverified sources, and treating anecdote as proven benefit.
Animal / preclinical only
No controlled human efficacy trials exist for BPC-157. Nearly all available data come from rodent models, with a substantial share from a single research group. This compound is sold and used entirely off-label and is not FDA-approved for any indication in humans.
Sikiric P et al. (2018). Current Pharmaceutical Design, 24(18), 1990-2001. Review of preclinical (rodent) research on BPC-157.